Utilization of ¹¹¹In‐Capromab pendetide SPECT‐CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy

Abstract

Abstract:The aim of this study was to evaluate the diagnostic value of a hybrid 111In-capromab pendetide fused computed tomography (CT) scan in detecting seminal vesicle invasion (SVI) in the setting of recurrent prostate cancer following primary in situ therapy. The study population comprised 59 patients, who biochemically failed primary in situ treatment based on American Society for Therapeutic Radiology and Oncology criteria. The patients underwent an 111In-capromab pendetide/CT scan at the time of biochemical failure with a prostate (12-core) and seminal vesicle (SV) (8-core) biopsy. The diagnostic properties of the scan and magnetic resonance imaging (MRI) in detecting SVI compared to an SV biopsy were calculated. In total, eight (14%) patients had a positive SV biopsy after primary in situ prostate cancer treatment. Nine (15%) patients had positive uptake of the scan in the SV. When comparing the SV scan results to the SV biopsy, the sensitivity, specificity, positive predictive value, and negative predictive value were 37.5%, 88.2%, 33.3%, and 90.0% (95% confidence interval: 0.44-0.81), respectively. In contrast, the ability of MRI to detect SVI was 50.0%, 81.3%, 40.0%, and 86.7% (95% confidence interval: 0.46-0.85), respectively. Although the sensitivity and positive predictive value of the 111 In-capromab pendetide/CT scan are low, its specificity and negative predictive value are high. Based on these findings, the ability of the 111 In-capromab pendetide/CT scan to detect SVI seems to be comparable with MRI.

Recent trends in antibody-based oncologic imaging

“…The sensitivity, specificity, positive (PPV) and negative predictive value (NPV) for [111]In-labeled prostascint SPECT-CT was found to be comparable to biopsy for detecting seminal vesicle invasion (SVI), but overall SPECT-CT was found to have limited ability in detecting SVI. SPECT was rarely used for quantitative imaging, primarily due to its poor photon statistic and difficulties in applying physical correction [8]. Seo et al .…”

Development and Characterization of 99mTc-scFvD2B as a Potential Radiopharmaceutical for SPECT Imaging of Prostate Cancer

“…Another strategy pursued in the development of PCa diagnostic agents exploits antibody-based constructs, as antibodies generally have a higher affinity for their targets than small peptides [ 19 ]. In fact, the monoclonal antibody (mAb) 111 In-capromab pendetide (ProstaScint ® Cytogen, Princeton, NJ, USA; murine origin) was the first Ab-based radiopharmaceutical approved by the Food and Drug Administration (FDA) for PCa diagnosis [ 20 , 21 , 22 , 23 ]. However, because ProstaScint ® recognizes an intracellular epitope, its binding sites are exposed only after apoptosis or necrosis processes.…”

Aplicação diagnóstica e terapêutica de um novo anticorpo anti-FGF2 em processos de angiogênese em melanoma experimental

“…111 In-capromab pendetide (ProstaScint®, EUA) é um anticorpo monoclonal (IgG1) murino 111 In-marcado com alvo no antígeno de membrana específico de próstata (PSA), aprovado pelo FDA em 1996 como agente de imagem capaz de detectar focos metastáticos bem como predizer recidiva da doença pós-prostatectomia radical. É indicado para localizar focos metastáticos em pacientes portadores de câncer de próstata de alto risco com altos níveis séricos de PSA, uma vez que CT e MRI tem baixa sensibilidade nessa determinação (Sodee DB et al, 1998;Kimura M et al, 2009).…”